中国恶性肿瘤整合诊治指南：前列腺癌（2026年版）

中国抗癌协会男性生殖系统肿瘤专业委员会

doi:10.19401/j.cnki.1007-3639.2026.09.010

您当前的位置：

首页 >

文章列表页 >

中国恶性肿瘤整合诊治指南：前列腺癌（2026年版）

指南与共识 | 更新时间：2026-10-23

- 中国恶性肿瘤整合诊治指南：前列腺癌（2026年版）
- Chinese Anti-Cancer Association guidelines for holistic integrative management of cancer: prostate cancer (2026 edition)
- 中国癌症杂志 2026年36卷第9期页码：911-968
- 作者机构：
- 作者简介：
- 基金信息：
  
  国家自然科学基金(U25C2039;82473192;82373355);上海申康医院发展中心2026年上海临床队列项目(SHDC2026CCS007);上海市东方英才计划拔尖项目科技平台-优秀学术带头人专题基金(BJKJ2024007);国家卫生健康委医药卫生科技发展研究中心创新药物上市后临床研究科研专项基金(WKZX2024CX104201)
- DOI：10.19401/j.cnki.1007-3639.2026.09.010
  中图分类号： R737.25
- 收稿：2026-08-25，
  
  修回：2026-09-24，
  
  录用：2026-09-29，
  
  纸质出版：2026-09-30
- 稿件说明：
移动端阅览
中国抗癌协会男性生殖系统肿瘤专业委员会. 中国恶性肿瘤整合诊治指南：前列腺癌（2026年版）［J］. 中国癌症杂志, 2026, 36（9）: 911-968.

Chinese Anti-Cancer Association Genital Oncology Committee. Chinese Anti-Cancer Association guidelines for holistic integrative management of cancer: prostate cancer（2026 edition）［J］. Chin Oncol, 2026, 36（9）: 911-968.
中国抗癌协会男性生殖系统肿瘤专业委员会. 中国恶性肿瘤整合诊治指南：前列腺癌（2026年版）［J］. 中国癌症杂志, 2026, 36（9）: 911-968. DOI： 10.19401/j.cnki.1007-3639.2026.09.010.

Chinese Anti-Cancer Association Genital Oncology Committee. Chinese Anti-Cancer Association guidelines for holistic integrative management of cancer: prostate cancer（2026 edition）［J］. Chin Oncol, 2026, 36（9）: 911-968. DOI： 10.19401/j.cnki.1007-3639.2026.09.010.

摘要

前列腺癌是全球男性常见恶性肿瘤之一。近年来，中国前列腺癌发病人数持续增加，初诊晚期患者比例仍相对较高，疾病负担日益加重。随着前列腺特异性抗原筛查、多参数磁共振成像、前列腺特异性膜抗原分子影像、分子病理学和基因检测等诊断技术的发展，以及手术、放疗、新型内分泌治疗、化疗、分子靶向治疗和放射性配体治疗等治疗手段的不断更新，前列腺癌的诊疗模式已逐步转向风险分层、精准治疗和全病程管理。为进一步规范中国前列腺癌的临床诊疗，中国抗癌协会男性生殖系统肿瘤专业委员会组织泌尿外科、肿瘤内科、放疗科、影像科、病理科、核医学科、中医科及康复医学等相关领域专家，在既往指南基础上开展定期更新。本指南已在国际实践指南注册与透明化平台完成注册。制定团队检索并评价国内外相关研究证据，参考国内外权威指南和专家共识，结合中国前列腺癌疾病特征、临床实践及医疗资源现状，经多学科专家讨论形成推荐意见。指南内容涵盖前列腺癌的流行病学与风险分层筛查、诊断与分期、病理学评价和分子检测、局限性前列腺癌治疗、根治性治疗后复发的诊疗、晚期前列腺癌系统治疗、骨相关事件管理、中西医结合治疗、康复及随访。2026年版重点更新了基于个体风险的早期检测策略、多参数磁共振成像和前列腺特异性抗原密度指导下的穿刺决策、分子分型与基因检测、局限性高危前列腺癌围手术期治疗、根治性治疗后复发的危险分层与挽救性治疗、转移性激素敏感性前列腺癌强化治疗、转移性去势抵抗性前列腺癌精准治疗及治疗序贯、前列腺特异性膜抗原靶向放射性配体治疗，以及中西医结合和全程康复管理等内容。本指南旨在为中国各级医疗机构及相关专业人员提供兼顾循证医学证据、临床可及性与患者个体特征的诊疗依据，促进前列腺癌的规范化、精准化和整合化管理。

Abstract

Prostate cancer is one of the most common malignancies among men worldwide. In China

the number of newly diagnosed cases continues to increase

while a relatively high proportion of patients still present with advanced disease

resulting in a growing disease burden. With advances in prostate-specific antigen-based early detection

multiparametric magnetic resonance imaging

prostate-specific membrane antigen-targeted molecular imaging

molecular pathology

and genomic testing

as well as the continuing development of surgery

radiotherapy

next-generation hormonal therapy

chemotherapy

molecularly targeted therapy

and radioligand therapy

the management of prostate cancer has progressively shifted toward risk stratification

precision treatment

and whole-course disease management. To further standardize the clinical management of prostate cancer in China

the Male Genitourinary Cancer Committee of the Chinese Anti-Cancer Association convened a multidisciplinary panel comprising experts in urologic surgery

medical oncology

radiation oncology

radiology

pathology

nuclear medicine

traditional Chinese medicine

and rehabilitation medicine to periodically update the previous version of the guideline. The guideline was registered on the Practice Guideline Registration for Transparency platform. The development group searched for and appraised relevant evidence from China and other countries

reviewed authoritative clinical practice guidelines and expert consensuses

and formulated recommendations through multidisciplinary discussions

taking into account the disease characteristics

clinical practice

and availability of healthcare resources in China. The guideline covers epidemiology and risk-adapted early detection

diagnosis and staging

pathological assessment and molecular testing

treatment of localized prostate cancer

management of recurrence after radical therapy

systemic treatment of advanced disease

management of skeletal-related events

integrative Chinese and Western medicine

rehabilitation

and follow-up. Major updates in the 2026 edition include risk-adapted early detection; biopsy decision-making guided by multiparametric magnetic resonance imaging and prostate-specific antigen density; molecular classification and genomic testing; perioperative treatment for high-risk localized disease; risk stratification and salvage treatment after radical therapy; treatment intensification for metastatic hormone-sensitive prostate cancer; precision treatment and therapeutic sequencing for metastatic castration-resistant prostate cancer; prostate-specific membrane antigen-targeted radioligand therapy; and integrative Chinese and Western medicine and whole-course rehabilitation. This guideline is intended to provide healthcare professionals at different levels of medical institutions in China with evidence-based and clinically applicable recommendations that incorporate individual patient characteristics

thereby promoting standardized

precise

and integrative management of prostate cancer.

关键词

Keywords

references

Rebello R J , Oing C , Knudsen K E , et al . Prostate cancer ［J］. Nat Rev Dis Primers , 2021 , 7 : 9 .

付振涛 , 郭晓雷 , 张思维 , 等 . 2015年中国前列腺癌发病与死亡分析［J］. 中华肿瘤杂志 , 2020 , 42 （ 9 ）: 718 - 722 .

Fu Z T , Guo X L , Zhang S W , et al . Statistical analysis of incidence and mortality of prostate cancer in China, 2015 ［J］. Chin J Oncol , 2020 , 42 （ 9 ）: 718 - 722 .

Zhou Y X , Zou Y X , Shen Q M , et al . A global review and perspective on prostate cancer survival: findings from survival studies of cancer registration data ［J］. J Natl Cancer Cent , 2026 , 6 （ 2 ）: 175 - 184 .

Han B F , Zheng R S , Zeng H M , et al . Cancer incidence and mortality in China, 2022 ［J］. J Natl Cancer Cent , 2024 , 4 （ 1 ）: 47 - 53 .

赫捷 , 陈万青 , 李霓 , 等 . 中国前列腺癌筛查与早诊早治指南（2022, 北京）［J］. 中国肿瘤 , 2022 , 31 （ 1 ）: 1 - 30 .

He J , Chen W Q , Li N , et al . China guideline for the screening and early detection of prostate cancer（2022, Beijing）［J］. China Cancer , 2022 , 31 （ 1 ）: 1 - 30 .

Cornford P , Van Den Bergh R C N , Briers E , et al . EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. part I: screening, diagnosis, and local treatment with curative intent ［J］. Eur Urol , 2024 , 86 （ 2 ）: 148 - 163 .

Tilki D , Van Den Bergh R C N , Briers E , et al . EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. part II-2026 update: treatment of relapsing and metastatic prostate cancer ［J］. Eur Urol , 2026 , 90 （ 3 ）: 270 - 290 .

Wang Z Y , Xu W H , Wan F N , et al . Prostate cancer in China: epidemiological trends, genomic insights, and future directions for optimized management ［J］. J Natl Cancer Cent , 2025 , 5 （ 5 ）: 474 - 485 .

Wei Y , Wu J L , Gu W J , et al . Germline DNA repair gene mutation landscape in Chinese prostate cancer patients ［J］. Eur Urol , 2019 , 76 （ 3 ）: 280 - 283 .

Zhu Y , Wei Y , Zeng H , et al . Inherited mutations in Chinese men with prostate cancer ［J］. J Natl Compr Canc Netw , 2021 , 20 （ 1 ）: 54 - 62 .

Rhodes S , Basourakos S P , Hu J C , et al . Trends in prebiopsy MRI utilization for prostate cancer detection ［J］. JAMA Oncol , 2026 : e263620 .

Ahmed H U , El-Shater Bosaily A , Brown L C , et al . Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer （PROMIS）: a paired validating confirmatory study ［J］. Lancet , 2017 , 389 （ 10071 ）: 815 - 822 .

Coelho T F , Bosma J S , Bozgo V , et al . Diagnostically calibrated AI image quality framework applied to prostate cancer detection at MRI ［J］. Radiology , 2026 , 320 （ 2 ）: e253360 .

Roobol M J , de Vos I I , Månsson M , et al . European study of prostate cancer screening: 23-year follow-up ［J］. N Engl J Med , 2025 , 393 （ 17 ）: 1669 - 1680 .

Cornford P , Van Den Bergh R C N , Briers E , et al . EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2026 update. part I: screening, diagnosis, and local treatment with curative intent ［J］. Eur Urol , 2026 , 90 （ 3 ）: 254 - 269 .

Tosoian J J , Zhang Y P , Xiao L B , et al . Development and validation of an 18-gene urine test for high-grade prostate cancer ［J］. JAMA Oncol , 2024 , 10 （ 6 ）: 726 - 736 .

Yuan M L , Moschovas M C , Joshi K , et al . A sensitive and specific non-invasive urine biomarker panel for prostate cancer detection ［J］. eBioMedicine , 2025 , 119 : 105895 .

Li H T , Wang X , Wu H , et al . Simultaneous noninvasive ultrasensitive detection of prostate specific antigen and lncRNA PCA3 using multiplexed dual optical microfibers with strong plasmonic nanointerfaces ［J］. Biosens Bioelectron , 2024 , 264 : 116672 .

Srinivasan S , Kryza T , Bock N , et al . A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer ［J］. Nat Commun , 2024 , 15 : 9587 .

Lazarovich A , Vigneswaran H , Palsdottir T , et al . A comparison of Stockholm3, serum biomarkers, and risk calculators to predict prostate cancer in a racially and ethnically diverse cohort: evaluation of the Stockholm3 multiethnic SEPTA trial ［J］. J Urol , 2025 , 213 （ 5 ）: 590 - 599 .

Ellis R J , Pugh S L , Yu J B , et al . Stereotactic body radiotherapy vs moderately hypofractionated IMRT for localized intermediate-risk prostate cancer: a randomized clinical trial ［J］. JAMA , 2026 , 336 （ 12 ）: 1029 - 1038 .

Krilaviciute A , Becker N , Carlsson S V , et al . Confirmation of prostate-specific antigen （PSA） values improves prostate cancer screening in early middle-aged men-data from the PROBASE trial ［J］. Eur Urol , 2026 : S0302-2838（26）02239 - 6 .

Saad F , Shore N , Vjaters E , et al . Darolutamide plus androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase 3 ARANOTE trial ［J］. Eur Urol , 2026 : S0302-2838（26）02313 - 4 .

Saha A , Bosma J S , Twilt J J , et al . Artificial intelligence and radiologists in prostate cancer detection on MRI （PI-CAI）: an international, paired, non-inferiority, confirmatory study ［J］. Lancet Oncol , 2024 , 25 （ 7 ）: 879 - 887 .

Jayaram A , Rashid M , Reid A H M , et al . Combined ctDNA and serum PSA for dynamic monitoring of metastatic prostate cancer starting first-line treatment: a prospective national cohort study ［J］. Nat Cancer , 2026 , 7 （ 6 ）: 915 - 927 .

Bayerl N , Adams L C , Cavallaro A , et al . Assessment of a fully-automated diagnostic AI software in prostate MRI: clinical evaluation and histopathological correlation ［J］. Eur J Radiol , 2024 , 181 : 111790 .

Jiao J H , Zhang J L , Li Z Y , et al . Prostate specific membrane antigen positron emission tomography in primary prostate cancer diagnosis: first-line imaging is afoot ［J］. Cancer Lett , 2022 , 548 : 215883 .

Lv J , Yu H J , Yin H Y , et al . A single-center, multi-factor, retrospective study to improve the diagnostic accuracy of primary prostate cancer using ［ 68 Ga］ Ga-PSMA-11 total-body PET/CT imaging ［J］. Eur J Nucl Med Mol Imaging , 2024 , 51 （ 3 ）: 919 - 927 .

焦健华 , 荆玉明 , 陈舰 , 等 . 68Ga-PSMA PET检查诊断前列腺癌患者淋巴结转移的研究进展［J］. 中华泌尿外科杂志 , 2022 , 43 （ 7 ）: 552 - 554 .

Jiao J H , Jing Y M , Chen J , et al . Research progress of detection of lymph node metastases by 68Ga-PSMA PET in prostate cancer patients ［J］. Chin J Urol , 2022 , 43 （ 7 ）: 552 - 554 .

Ko H , Glied S A . Robotic prostatectomy and prostate cancer-related Medicaid spending: evidence from New York State ［J］. J Gen Intern Med , 2021 , 36 （ 11 ）: 3388 - 3394 .

刘容 , 翁铭芳 , 郭春雨 , 等 . 机器人辅助与普通腹腔镜前列腺癌根治术对老年患者尿控功能的影响［J］. 中华腔镜泌尿外科杂志（电子版）, 2023 , 17 （ 2 ）: 169 - 172 .

Liu R , Weng M F , Guo C Y , et al . Effects of robot assisted and pure laparoscopic radical prostatectomy on urinary control function in elderly patients ［J］. Chin J Endourol Electronic Ed , 2023 , 17 （ 2 ）: 169 - 172 .

薛梅平 , 王春樱 , 胡文婷 , 等 . 机器人辅助手术改善腹腔镜下前列腺癌根治术患者术后尿控功能恢复程度的临床疗效观察［J］. 中华男科学杂志 , 2022 , 28 （ 6 ）: 501 - 505 .

Xue M P , Wang C Y , Hu W T , et al . Robot-assisted laparoscopic radical prostatectomy helps improve postoperative urinary continence recovery in patients with prostate cancer ［J］. Natl J Androl , 2022 , 28 （ 6 ）: 501 - 505 .

Buteau J P , Moon D , Fahey M T , et al . Effect of ［ 68 Ga］ Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI （PRIMARY2）: a multicentre, non-inferiority, phase 3, randomised controlled trial ［J］. Lancet Oncol , 2026 , 27 （ 7 ）: 839 - 848 .

Hamdy F C , Donovan J L , Lane J A , et al . 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer ［J］. N Engl J Med , 2016 , 375 （ 15 ）: 1415 - 1424 .

Abiodun-Ojo O A , Jani A B , Goyal S , et al . 18 F-fluciclovine or 68 Ga-PSMA-11 PET/CT-guided salvage radiotherapy changes in postprostatectomy biochemical recurrence: secondary analysis of the EMPIRE-2 trial ［J］. Radiology , 2026 , 319 （ 3 ）: e251874 .

Klotz L , Vesprini D , Sethukavalan P , et al . Long-term follow-up of a large active surveillance cohort of patients with prostate cancer ［J］. J Clin Oncol , 2015 , 33 （ 3 ）: 272 - 277 .

Jani A B , Dhere V R , Goyal S , et al . ［ 18 F］-fluciclovine or ［ 68 Ga］-PSMA-11 molecular imaging to guide dose escalation of salvage radiotherapy after radical prostatectomy for prostate cancer: the EMPIRE-2 trial ［J］. Eur Urol , 2026 , 89 （ 4 ）: 368 - 377 .

Wilt T J , Jones K M , Barry M J , et al . Follow-up of prostatectomy versus observation for early prostate cancer ［J］. N Engl J Med , 2017 , 377 （ 2 ）: 132 - 142 .

Lin D W , Carlsson S , Filson C P , et al . Updates to early detection of prostate cancer: AUA/SUO guideline （2026）［J］. J Urol , 2026 , 215 （ 5 ）: 491 - 501 .

Schoots I G , Ahmed H U , Albers P , et al . Magnetic resonance imaging–based biopsy strategies in prostate cancer screening: a systematic review ［J］. Eur Urol , 2025 , 88 （ 3 ）: 247 - 260 .

Lomas D J , Ahmed H U . All change in the prostate cancer diagnostic pathway ［J］. Nat Rev Clin Oncol , 2020 , 17 （ 6 ）: 372 - 381 .

Newcomb L F , Schenk J M , Zheng Y Y , et al . Long-term outcomes in patients using protocol-directed active surveillance for prostate cancer ［J］. JAMA , 2024 , 331 （ 24 ）: 2084 - 2093 .

Godtman R A , Pettersson C , Svensson L , et al . Men’s acceptance of screening for prostate cancer with prostate-specific antigen, magnetic resonance imaging, and prostate biopsy ［J］. Eur Urol Oncol , 2024 , 7 （ 3 ）: 553 - 562 .

Zheng B , Zhu J , Xu M , et al . Quantifying the heterogeneity of TRUS-visible lesions for predicting prostate cancer: a multicenter preliminary study ［J］. Acad Radiol , 2026 , 33 （ 7 ）: 2946 - 2957 .

WHO Classification of Tumours Editorial Board . Urinary and Male Genital Tumours ［M］. 5th ed . Lyon : IARC , 2022 .

Santiago I , Rivas J G . Re: EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer ［J］. Eur Urol , 2026 , 89 （ 1 ）: 100 - 102 .

Shi K S , Ji X , Yabroff K R , et al . Spillover effects of medicaid expansion on insurance coverage, diagnosis, and survival among low-income older patients with cancer ［J］. J Natl Compr Canc Netw , 2026 : 1 - 11 .

Spratt D E , Srinivas S , Adra N , et al . NCCN guidelines insights: prostate cancer, version 5.2026 ［J］. J Natl Compr Canc Netw , 2026 , 24 （ 5 ）: 140 - 149 .

Wang Z P , Zhu S , Zhao J G , et al . The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer ［J］. Prostate , 2021 , 81 （ 15 ）: 1191 - 1201 .

Leung D H L , Adzavon Y M , Chu G , et al . ADT and activation of HGF and WNT axes in double-null prostate cancer ［J］. Nat Rev Urol , 2026 , 23 （ 8 ）: 533 - 541 .

Brevi A , Lorenzoni M , Caputo S , et al . Intercepting YAP activation in prostate cancer blocks neuroendocrine progression ［J］. Cancer Res , 2026 , 86 （ 12 ）: 2860 - 2877 .

Han M , Li F , Zhang Y H , et al . FOXA2 drives lineage plasticity and KIT pathway activation in neuroendocrine prostate cancer ［J］. Cancer Cell , 2022 , 40 （ 11 ）: 1306 - 1323.e8 .

Fang B W , Li X M , Lu Y , et al . EGFR- and HER3-targeted bispecific antibody-drug conjugate demonstrates antitumor activity in metastatic castration-resistant prostate cancer ［J］. J Clin Invest , 2026 , 136 （ 11 ）: e201090 .

Van Leenders G J L H , van der Kwast T H , Grignon D J , et al . The 2019 international society of urological pathology （ISUP） consensus conference on grading of prostatic carcinoma ［J］. Am J Surg Pathol , 2020 , 44 （ 8 ）: e87 - e99 .

Collins K , Gupta S , Cheng L . Updates in bladder and prostate pathology: diagnostic consensus and clinical relevance ［J］. Hum Pathol , 2026 , 169 : 106018 .

Epstein J I , Zelefsky M J , Sjoberg D D , et al . A contemporary prostate cancer grading system: a validated alternative to the Gleason score ［J］. Eur Urol , 2016 , 69 （ 3 ）: 428 - 435 .

Buyyounouski M K , Choyke P L , McKenney J K , et al . Prostate cancer-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual ［J］. CA Cancer J Clin , 2017 , 67 （ 3 ）: 245 - 253 .

Fanti S , Goffin K , Hadaschik B A , et al . Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer ［J］. Eur J Nucl Med Mol Imaging , 2021 , 48 （ 2 ）: 469 - 476 .

Giri V N , Morgan T M , Morris D S , et al . Genetic testing in prostate cancer management: considerations informing primary care ［J］. CA Cancer J Clin , 2022 , 72 （ 4 ）: 360 - 371 .

Pritchard C C , Mateo J , Walsh M F , et al . Inherited DNA-repair gene mutations in men with metastatic prostate cancer ［J］. N Engl J Med , 2016 , 375 （ 5 ）: 443 - 453 .

Agarwal N , Matsubara N , Azad A A , et al . PARP and androgen-signaling inhibition plus ADT in metastatic prostate cancer ［J］. N Engl J Med , 2026 , 395 （ 5 ）: 427 - 439 .

Abida W , Cheng M L , Armenia J , et al . Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade ［J］. JAMA Oncol , 2019 , 5 （ 4 ）: 471 - 478 .

Gruber A J , Olsen A V , Hernando B , et al . Integrated signatures define mutational processes in prostate cancer ［J］. Nature , 2026 : 1 - 11 .

Eggener S E , Rumble R B , Armstrong A J , et al . Molecular biomarkers in localized prostate cancer: ASCO guideline ［J］. J Clin Oncol , 2020 , 38 （ 13 ）: 1474 - 1494 .

Wang Z , Ge Q , Mo R , et al . Spatial and maturity heterogeneity of tertiary lymphoid structures shapes immune microenvironment and progression in prostate cancer ［J］. J Natl Cancer Cent , 2025 , 5 （ 5 ）: 501 - 514 .

De Bono J , Mateo J , Fizazi K , et al . Olaparib for metastatic castration-resistant prostate cancer ［J］. N Engl J Med , 2020 , 382 （ 22 ）: 2091 - 2102 .

Agarwal N , Azad A A , Carles J , et al . Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer （TALAPRO-2）: a randomised, placebo-controlled, phase 3 trial ［J］. Lancet , 2023 , 402 （ 10398 ）: 291 - 303 .

Antonarakis E S , Piulats J M , Gross-Goupil M , et al . Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study ［J］. J Clin Oncol , 2020 , 38 （ 5 ）: 395 - 405 .

Jamaspishvili T , Berman D M , Ross A E , et al . Clinical implications of PTEN loss in prostate cancer ［J］. Nat Rev Urol , 2018 , 15 （ 4 ）: 222 - 234 .

Tolmeijer S H , Maurice-Dror C , Sandhu S , et al . Germline CDK12 variants in aggressive prostate cancer ［J］. Cancer Discov , 2026 .

Sweeney C , Bracarda S , Sternberg C N , et al . Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer （IPATential150）: a multicentre, randomised, double-blind, phase 3 trial ［J］. Lancet , 2021 , 398 （ 10295 ）: 131 - 142 .

Wyatt A W , Azad A A , Volik S V , et al . Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer ［J］. JAMA Oncol , 2016 , 2 （ 12 ）: 1598 - 1606 .

Antonarakis E S , Lu C X , Wang H , et al . AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer ［J］. N Engl J Med , 2014 , 371 （ 11 ）: 1028 - 1038 .

Schweizer M T , Sivakumar S , Tukachinsky H , et al . Concordance of DNA repair gene mutations in paired primary prostate cancer samples and metastatic tissue or cell-free DNA ［J］. JAMA Oncol , 2021 , 7 （ 9 ）: 1 - 5 .

Seed G , Beije N , Yuan W , et al . Elucidating acquired PARP inhibitor resistance in advanced prostate cancer ［J］. Cancer Cell , 2024 , 42 （ 12 ）: 2113 - 2123.e4 .

Goodall J , Mateo J , Yuan W , et al . Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition ［J］. Cancer Discov , 2017 , 7 （ 9 ）: 1006 - 1017 .

Guo H S , Vuille J A , Wittner B S , et al . DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and CTCs ［J］. Cell , 2023 , 186 （ 13 ）: 2765 - 2782.e28 .

Jensen K , Konnick E Q , Schweizer M T , et al . Association of clonal hematopoiesis in DNA repair genes with prostate cancer plasma cell-free DNA testing interference ［J］. JAMA Oncol , 2021 , 7 （ 1 ）: 107 - 110 .

Casanova-Salas I , Aguilar D , Cordoba-Terreros S , et al . Circulating tumor extracellular vesicles to monitor metastatic prostate cancer genomics and transcriptomic evolution ［J］. Cancer Cell , 2024 , 42 （ 7 ）: 1301 - 1312.e7 .

Leone G , Wong Y N S , Jones R J , et al . Nivolumab and ipilimumab for metastatic castration-resistant prostate cancer with an immunogenic signature: the multicenter, two-cohort, phase II NEPTUNES study ［J］. J Clin Oncol , 2025 , 43 （ 28 ）: 3070 - 3080 .

Karzai F , VanderWeele D , Madan R A , et al . Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations ［J］. J Immunother Cancer , 2018 , 6 （ 1 ）: 141 .

Hussain M , Daignault-Newton S , Twardowski P W , et al . Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: results from NCI 9012 ［J］. J Clin Oncol , 2018 , 36 （ 10 ）: 991 - 999 .

Chen W S , Aggarwal R , Zhang L , et al . Genomic drivers of poor prognosis and enzalutamide resistance in metastatic castration-resistant prostate cancer ［J］. Eur Urol , 2019 , 76 （ 5 ）: 562 - 571 .

Chi K N , Agarwal N , Bjartell A , et al . Apalutamide for metastatic, castration-sensitive prostate cancer ［J］. N Engl J Med , 2019 , 381 （ 1 ）: 13 - 24 .

Wang Z Y , Ge Q T , Anwaier A , et al . Hsa_circ_0038737 promotes PARPi resistance in castration-resistant prostate cancer via IGF 2 BP 3 -mediated DNPH1 mRNA stabilization ［J］. Mol Cancer , 2025 , 24 （ 1 ）: 238 .

Antonarakis E S , Lu C X , Luber B , et al . Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide ［J］. J Clin Oncol , 2017 , 35 （ 19 ）: 2149 - 2156 .

Wise D R , Pachynski R K , Denmeade S R , et al . A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer （mCRPC）［J］. Prostate Cancer Prostatic Dis , 2025 , 28 （ 2 ）: 363 - 369 .

Plym A , Penney K L , Kalia S , et al . Evaluation of a multiethnic polygenic risk score model for prostate cancer ［J］. J Natl Cancer Inst , 2022 , 114 （ 5 ）: 771 - 774 .

蔡欣旸 , 范宇 , 李永红 . 前列腺癌主动监测的研究进展［J］. 中华泌尿外科杂志 , 2024 , 45 （ 6 ）: 477 - 480 .

Cai X Y , Fan Y , Li Y H . The progress of active surveillance of prostate cancer ［J］. Chin J Urol , 2024 , 45 （ 6 ）: 477 - 480 .

Checcucci E , De Cillis S , Alladio E , et al . Ten-year functional and oncological outcomes of a prospective randomized controlled trial comparing laparoscopic versus robot-assisted radical prostatectomy ［J］. Prostate , 2024 , 84 （ 9 ）: 832 - 841 .

Haney C M , Kowalewski K F , Westhoff N , et al . Robot-assisted versus conventional laparoscopic radical prostatectomy: a systematic review and meta-analysis of randomised controlled trials ［J］. Eur Urol Focus , 2023 , 9 （ 6 ）: 930 - 937 .

Lestingi J F P , Guglielmetti G B , Trinh Q D , et al . Extended versus limited pelvic lymph node dissection during radical prostatectomy for intermediate- and high-risk prostate cancer: early oncological outcomes from a randomized phase 3 trial ［J］. Eur Urol , 2021 , 79 （ 5 ）: 595 - 604 .

Shenderov E , de Marzo A M , Lotan T L , et al . Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial ［J］. Nat Med , 2023 , 29 （ 4 ）: 888 - 897 .

Zhang X Y , Zhou F , Lu T , et al . Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk and locally advanced prostate cancer: a multicenter, open-label, single-arm, phase II trial ［J］. World J Urol , 2025 , 43 （ 1 ）: 58 .

Devos G , Devlies W , De Meerleer G , et al . Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer ［J］. Nat Rev Urol , 2021 , 18 （ 12 ）: 739 - 762 .

Jones L W , Moskowitz C S , Lee C P , et al . Neoadjuvant exercise therapy in prostate cancer: a phase 1, decentralized nonrandomized controlled trial ［J］. JAMA Oncol , 2024 , 10 （ 9 ）: 1187 - 1194 .

陈剑超 , 祁峰 , 郑雨潇 , 等 . 新辅助化疗联合内分泌治疗在局部进展期前列腺癌中的临床疗效［J］. 临床泌尿外科杂志 , 2025 , 40 （ 6 ）: 491 - 496 .

Chen J C , Qi F , Zheng Y X , et al . Clinical efficacy of neoadjuvant chemo-hormonal therapy in locally advanced prostate cancer ［J］. J Clin Urol , 2025 , 40 （ 6 ）: 491 - 496 .

Eastham J A , Heller G , Halabi S , et al . Cancer and leukemia group B 90203 （alliance）: radical prostatectomy with or without neoadjuvant chemohormonal therapy in localized, high-risk prostate ca ncer ［J］. J Clin Oncol , 2020 , 38 （ 26 ）: 3042 - 3050 .

Fleshner N E , Hansen A R , Chin J , et al . Randomized phase II trial of neoadjuvant abiraterone plus or minus cabazitaxel in high-risk prostate cancer: ACDC-RP ［J］. J Clin Oncol , 2022 , 40 （ 6_suppl ）: 224 .

Ohaegbulam K C , Post C M , Farris P E , et al . Safety and efficacy of neoadjuvant docetaxel and radiotherapy in localized high-risk prostate cancer: results from a prospective pilot study ［J］. Am J Clin Oncol , 2025 , 48 （ 2 ）: 75 - 82 .

Liu W , Yao Y , Liu X , et al . Neoadjuvant hormone therapy for patients with high-risk prostate cancer: a systematic review and meta-analysis ［J］. Asian J Androl , 2021 , 23 （ 4 ）: 429 - 436 .

Bolla M , van Poppel H , Tombal B , et al . Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial （EORTC trial 22911）［J］. Lancet , 2012 , 380 （ 9858 ）: 2018 - 2027 .

Wiegel T , Bartkowiak D , Bottke D , et al . Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial ［J］. Eur Urol , 2014 , 66 （ 2 ）: 243 - 250 .

Hackman G , Taari K , Tammela T L , et al . Randomised trial of adjuvant radiotherapy following radical prostatectomy versus radical prostatectomy alone in prostate cancer patients with positive margins or extracapsular extension ［J］. Eur Urol , 2019 , 76 （ 5 ）: 586 - 595 .

Kishan A U , Sun Y L , Parker C C , et al . Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis ［J］. Lancet , 2026 , 407 （ 10533 ）: 1059 - 1071 .

万方宁 , 戴波 , 叶碧然 , 等 . 前列腺癌冷冻治疗的远期疗效及预测因素［J］. 中华泌尿外科杂志 , 2024 , 45 （ 6 ）: 451 - 455 .

Wan F N , Dai B , Ye B R , et al . Long-term prognostic predictors of prostate cancer patients who underwent cryotherapy ［J］. Chin J Urol , 2024 , 45 （ 6 ）: 451 - 455 .

Sherry A D , Siddiqui B A , Haymaker C , et al . Continuous androgen deprivation therapy with or without metastasis-directed therapy for oligometastatic prostate cancer: the multicenter phase 2 randomized EXTEND trial ［J］. Eur Urol , 2025 , 88 （ 5 ）: 496 - 509 .

Siva S , Bressel M , Sidhom M , et al . Stereotactic ablative body radiotherapy for primary kidney cancer （TROG 15.03 FASTRACK II）: a non-randomised phase 2 trial ［J］. Lancet Oncol , 2024 , 25 （ 3 ）: 308 - 316 .

Donaldson I A , Alonzi R , Barratt D , et al . Focal therapy: patients, interventions, and outcomes: a report from a consensus meeting ［J］. Eur Urol , 2015 , 67 （ 4 ）: 771 - 777 .

Blazevski A , Scheltema M J , Yuen B , et al . Oncological and quality-of-life outcomes following focal irreversible electroporation as primary treatment for localised prostate cancer: a biopsy-monitored prospective cohort ［J］. Eur Urol Oncol , 2020 , 3 （ 3 ）: 283 - 290 .

de la Rosette J , Dominguez-Escrig J , Zhang K , et al . A multicenter, randomized, single-blind, 2-arm intervention study evaluating the adverse events and quality of life after irreversible electroporation for the ablation of localized low-intermediate risk prostate cancer ［J］. J Urol , 2023 , 209 （ 2 ）: 347 - 353 .

Scheltema M J V , Stricker P D . Prospective multicentre validation of focal irreversible electroporation as an attractive treatment option for localised intermediate-risk prostate cancer ［J］. Eur Urol , 2026 , 89 （ 1 ）: 69 - 70 .

McClure T D , Wang S , Ballman K V , et al . Combination of radiation therapy and irreversible electroporation for intermediate-risk prostate cancer （RTIRE）: a phase 1 trial ［J］. Radiology , 2026 , 320 （ 1 ）: e250848 .

George A K , Miocinovic R , Patel A R , et al . Irreversible electroporation for prostate tissue ablation in patients with intermediate-risk prostate cancer: results from the PRESERVE trial ［J］. Eur Urol , 2026 , 89 （ 1 ）: 57 - 68 .

Wang H F , Xue W , Yan W G , et al . Extended focal ablation of localized prostate cancer with high-frequency irreversible electroporation: a nonrandomized controlled trial ［J］. JAMA Surg , 2022 , 157 （ 8 ）: 693 - 700 .

Isharwal S , Greene K L . Prostate cancer recurrence and persistence after irreversible electroporation focal ablation ［J］. JAMA Surg , 2023 , 158 （ 4 ）: 349 .

Scheltema M J , Katelaris A , Stricker P D . Salvage irreversible electroporation for radio-recurrent prostate cancer ［J］. Nat Rev Urol , 2023 , 20 （ 9 ）: 517 - 518 .

Marvaso G , Corrao G , Zaffaroni M , et al . ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer （RADIOSA）: a randomised, open-label, phase 2 clinical trial ［J］. Lancet Oncol , 2025 , 26 （ 3 ）: 300 - 311 .

Tang C , Sherry A D , Haymaker C , et al . Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: the EXTEND phase 2 randomized clinical trial ［J］. JAMA Oncol , 2023 , 9 （ 6 ）: 825 .

Xu W H , Zhou S Q , Zhang H L . Prostate-specific membrane antigen PET-guided salvage radiotherapy-precision or prematurity ［J］. JAMA Oncol , 2026 , 12 （ 4 ）: 421 - 422 .

Francolini G , Allegra A G , Detti B , et al . Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: a randomized phase II trial （ARTO）［J］. J Clin Oncol , 2023 , 41 （ 36 ）: 5561 - 5568 .

Armstrong A J , Petrylak D P , Shore N D , et al . ARCHES: 5-year follow-up overall survival （OS） analysis of enzalutamide （ENZA） plus androgen-deprivation therapy （ADT） in patients （pts） with metastatic hormone-sensitive prostate cancer （mHSPC）［J］. J Clin Oncol , 2025 , 43 （ 16_suppl ）: 5005 .

Zhang A Y , Davis I D , Thomas H , et al . 8-year outcomes of enzalutamide （ENZA） versus a non-steroidal anti-androgen （NSAA） for metastatic, hormone-sensitive prostate cancer （ENZAMET; ANZUP 1304）［J］. J CLIN ONCOL , 2025 , 43 （ 16_suppl ）: 5090 .

Wang Y , Cui Y D , Li Y H , et al . Risk of seizure in patients with prostate cancer treated with enzalutamide in China: a noninterventional study ［J］. Ther Adv Drug Saf , 2025 , 16 : 20420986251391078 .

Dong Q , Li L , Li Z H , et al . Evaluation of PSA decline patterns in the Chinese subgroup of LIBERTAS, a phase 3 study of apalutamide plus continuous versus intermittent androgen deprivation therapy in metastatic castration-sensitive prostate cancer ［J］. J Clin Oncol , 2026 , 44 （ 7_suppl ）: 154 .

Wang H K , Jiang S S , Luo H , et al . Patient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients （CHART）: a randomized, phase 3 study ［J］. Sig Transduct Target Ther , 2024 , 9 : 351 .

Bian X J , Gu W J , Zhang X P , et al . Correlation of PSA and survival in metastatic hormone-sensitive prostate cancer treated with rezvilutamide plus ADT in the CHART trial ［J］. Med , 2025 , 6 （ 2 ）: 100520 .

Saad F , Vjaters E , Shore N , et al . Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial ［J］. J Clin Oncol , 2024 , 42 （ 36 ）: 4271 - 4281 .

Aziz M K , Molony D , Monlezun D , et al . Prostate cancer therapy cardiotoxicity map （PROXMAP） for advanced disease states: a systematic review and network meta-analysis with Bayesian modeling of treatment histories ［J］. Eur Urol , 2025 , 87 （ 1 ）: 15 - 26 .

Wang B , Ye D , Guo H , et al . 490MO Niraparib （NIRA） and abiraterone acetate plus prednisone （AAP） in Chinese patients with breast cancer susceptibility gene （BRCA） altered metastatic castration-sensitive prostate cancer （mCSPC）: subgroup analysis of the phase Ⅲ AMPLITUDE trial ［J］. Ann Oncol , 2025 , 36 : S1909 .

Zhang A Y , Thomas H , Begbie S , et al . Eight-year outcomes of testosterone suppression plus enzalutamide or a nonsteroidal antiandrogen for metastatic hormone-sensitive prostate cancer （ENZAMET; ANZUP 1304）［J］. Ann Oncol , 2026 : S0923-7534（26）01410 - 9 .

Fizazi K , Clarke N W , de Santis M , et al . Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase Ⅲ study ［J］. Ann Oncol , 2026 , 37 （ 1 ）: 53 - 68 .

Rescigno P , Porta N , Finneran L , et al . Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: results from the randomized phase II RE-AKT trial ［J］. Eur J Cancer , 2024 , 205 : 114103 .

Morris M J , Gupta S , Tagawa S T , et al . Health-related quality of life, pain, and symptomatic skeletal events in the phase 3 PSMAddition study of ［ 177 Lu］ Lu-PSMA-617 （ 177 Lu-PSMA-617） combined with ADT and ARPI in patients with PSMA-positive mHSPC ［J］. J Clin Oncol , 2026 , 44 （ 7_suppl ）: 18 .

Tagawa S T , Sartor O , Piulats J M , et al . Phase Ⅲ trial of ［ 177 Lu］ Lu-PSMA-617 combined with ADT+ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer （PSMAddition）［J］. Ann Oncol , 2025 , 36 : S1627 - S1628 .

Wu J L , Wei Y , Pan J , et al . Prevalence of comprehensive DNA damage repair gene germline mutations in Chinese prostate cancer patients ［J］. Int J Cancer , 2021 , 148 （ 3 ）: 673 - 681 .

Ge Q T , Wang Z D , Wang Y Y , et al . Integrative single-cell and spatial transcriptomics with explainable AI reveal lethal prognostic axis in prostate cancer ［J］. NPJ Digit Med , 2026 , 9 （ 1 ）: 119 .

Ryan C J , Smith M R , de Bono J S , et al . Abiraterone in metastatic prostate cancer without previous chemotherapy ［J］. N Engl J Med , 2013 , 368 （ 2 ）: 138 - 148 .

Ryan C J , Smith M R , Fizazi K , et al . Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer （COU-AA-302）: final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study ［J］. Lancet Oncol , 2015 , 16 （ 2 ）: 152 - 160 .

De Bono J S , Logothetis C J , Molina A , et al . Abiraterone and increased survival in metastatic prostate cancer ［J］. N Engl J Med , 2011 , 364 （ 21 ）: 1995 - 2005 .

Fizazi K , Scher H I , Molina A , et al . Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study ［J］. Lancet Oncol , 2012 , 13 （ 10 ）: 983 - 992 .

Pan J , Zhao J O , Ni X D , et al . Heterogeneity of ［ 68 Ga］ Ga-PSMA-11 PET/CT in metastatic castration-resistant prostate cancer: genomic characteristics and association with abiraterone response ［J］. Eur J Nucl Med Mol Imaging , 2023 , 50 （ 6 ）: 1822 - 1832 .

Gillessen S , Turco F , Davis I D , et al . Management of patients with advanced prostate cancer: report from the 2024 Advanced Prostate Cancer Consensus Conference （APCCC）［J］. Eur Urol , 2025 , 87 （ 2 ）: 157 - 216 .

Pu Y S , Ahn H , Han W Q , et al . Enzalutamide in chemotherapy-Naïve metastatic castration-resistant prostate cancer: an Asian multiregional, randomized study ［J］. Adv Ther , 2022 , 39 （ 6 ）: 2641 - 2656 .

Pan J , Wang B H , Zhu B , et al . Consolidative therapy for PSMA-avid lesions after 3 cycles of apalutamide plus androgen deprivation in metastatic hormone-sensitive prostate cancer: a prospective phase 2 single-arm trial ［J］. Eur J Nucl Med Mol Imaging , 2026 , 53 （ 11 ）: 6429 - 6441 .

Merseburger A S , Attard G , Åström L , et al . Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel （PRESIDE）: an international, randomised, phase 3b study ［J］. Lancet Oncol , 2022 , 23 （ 11 ）: 1398 - 1408 .

Zhang T W , Wang B H , Wei Y , et al . Neoadjuvant fuzuloparib combined with abiraterone for localized high-risk prostate cancer （FAST-PC）: a single-arm phase 2 study ［J］. Cell Rep Med , 2025 , 6 （ 3 ）: 102018 .

Fizazi K , Massard C , Bono P , et al . Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer （ARADES）: an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial ［J］. Lancet Oncol , 2014 , 15 （ 9 ）: 975 - 985 .

Qin X J , Ji D M , Gu W J , et al . Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trial ［J］. BMC Med , 2022 , 20 （ 1 ）: 84 .

Wu J L , Li X H , Gu C Y , et al . Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase Ⅲ HC-1119-04 trial ［J］. Sig Transduct Target Ther , 2026 , 11 （ 1 ）: 131 .

Pan J , Wu J L , Wang B H , et al . Interlesional response heterogeneity is associated with the prognosis of abiraterone treatment in metastatic castration-resistant prostate cancer ［J］. Med , 2024 , 5 （ 12 ）: 1475 - 1484.e3 .

Yang X W , Chen H , Xu D Y , et al . Efficacy and safety of Androgen Deprivation Therapy （ADT） combined with modified docetaxel chemotherapy versus ADT combined with standard docetaxel chemotherapy in patients with metastatic castration-resistant prostate cancer: study protocol for a multicentre prospective randomized controlled trial ［J］. BMC Cancer , 2022 , 22 （ 1 ）: 177 .

Eisenberger M , Hardy-Bessard A C , Kim C S , et al . Phase Ⅲ Study Comparing a Reduced Dose of Cabazitaxel （20 mg/m 2 ） and the Currently Approved Dose （25 mg/m 2 ） in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA ［J］. J Clin Oncol , 2017 , 35 （ 28 ）: 3198 - 3206 .

Corn P G , Heath E I , Zurita A , et al . Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial ［J］. Lancet Oncol , 2019 , 20 （ 10 ）: 1432 - 1443 .

Aparicio A M , Harzstark A L , Corn P G , et al . Platinum-based chemotherapy for variant castrate-resistant prostate cancer ［J］. Clin Cancer Res , 2013 , 19 （ 13 ）: 3621 - 3630 .

Mazzone E , Thomson A , Chen D C , et al . The role of prostate-specific membrane antigen positron emission tomography for assessment of local recurrence and distant metastases in patients with biochemical recurrence of prostate cancer after definitive treatment: a systematic review and meta-analysis ［J］. Eur Urol , 2025 , 88 （ 2 ）: 129 - 141 .

Saad F , Clarke N W , Oya M , et al . Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer （PROpel）: final prespecified overall survival results of a randomised, double-blind, phase 3 trial ［J］. Lancet Oncol , 2023 , 24 （ 10 ）: 1094 - 1108 .

Hussain M , Mateo J , Fizazi K , et al . Survival with olaparib in metastatic castration-resistant prostate cancer ［J］. N Engl J Med , 2020 , 383 （ 24 ）: 2345 - 2357 .

Dong B J , Yang B , Chen W , et al . Olaparib for Chinese metastatic castration-resistant prostate cancer: a real-world study of efficacy and gene predictive analysis ［J］. Med Oncol , 2022 , 39 （ 5 ）: 96 .

Naqvi S A A , Riaz I B , Bibi A , et al . Heterogeneity of the treatment effect with PARP inhibitors in metastatic castration-resistant prostate cancer: a living interactive systematic review and meta-analysis ［J］. Eur Urol , 2025 , 87 （ 6 ）: 626 - 640 .

Fizazi K , Piulats J M , Reaume M N , et al . Rucaparib or physician’s choice in metastatic prostate cancer ［J］. N Engl J Med , 2023 , 388 （ 8 ）: 719 - 732 .

Chi K N , Castro E , Attard G , et al . Niraparib and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: final overall survival analysis for the phase 3 MAGNITUDE trial ［J］. Eur Urol Oncol , 2025 , 8 （ 4 ）: 986 - 998 .

Agarwal N , Azad A A , Carles J , et al . Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial ［J］. Lancet , 2025 , 406 （ 10502 ）: 447 - 460 .

Fizazi K , Azad A A , Matsubara N , et al . Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial ［J］. Lancet , 2025 , 406 （ 10502 ）: 461 - 474 .

Parker C , Nilsson S , Heinrich D , et al . Alpha emitter radium-223 and survival in metastatic prostate cancer ［J］. N Engl J Med , 2013 , 369 （ 3 ）: 213 - 223 .

Heidenreich A , Gillessen S , Heinrich D , et al . Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program ［J］. BMC Cancer , 2019 , 19 （ 1 ）: 12 .

Tombal B , Choudhury A , Saad F , et al . Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial ［J］. Ann Oncol , 2025 , 36 （ 9 ）: 1058 - 1067 .

Gillessen S , Gallardo E , Choudhury A , et al . Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer ［J］. Ann Oncol , 2026 , 37 （ 5 ）: 736 - 742 .

Sartor O , de Bono J , Chi K N , et al . Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer ［J］. N Engl J Med , 2021 , 385 （ 12 ）: 1091 - 1103 .

Morris M J , Castellano D , Herrmann K , et al . 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer （PSMAfore）: a phase 3, randomised, controlled trial ［J］. Lancet , 2024 , 404 （ 10459 ）: 1227 - 1239 .

Fizazi K , Chi K N , Shore N D , et al . Final overall survival and safety analyses of the phase Ⅲ PSMAfore trial of ［ 177 Lu］ Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer ［J］. Ann Oncol , 2025 , 36 （ 11 ）: 1319 - 1330 .

Wang G C , Zang J , Jiang Y Y , et al . A single-arm, low-dose, prospective study of 177 Lu-EB-PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer ［J］. J Nucl Med , 2023 , 64 （ 4 ）: 611 - 617 .

Zang J , Wang G C , Zhao T Z , et al . A phase 1 trial to determine the maximum tolerated dose and patient-specific dosimetry of ［ 177 Lu］ Lu-LNC1003 in patients with metastatic castration-resistant prostate cancer ［J］. Eur J Nucl Med Mol Imaging , 2024 , 51 （ 3 ）: 871 - 882 .

Kantoff P W , Higano C S , Shore N D , et al . Sipuleucel-T immunotherapy for castration-resistant prostate cancer ［J］. N Engl J Med , 2010 , 363 （ 5 ）: 411 - 422 .

Jiang S S , Tian Y , Guo H Q , et al . A randomized study of apalutamide in Chinese patients with non-metastatic castration-resistant prostate cancer ［J］. iScience , 2025 , 28 （ 8 ）: 113166 .

Bögemann M , Shore N D , Smith M R , et al . Efficacy and safety of darolutamide in patients with nonmetastatic castration-resistant prostate cancer stratified by prostate-specific antigen doubling time: planned subgroup analysis of the phase 3 ARAMIS trial ［J］. Eur Urol , 2023 , 83 （ 3 ）: 212 - 221 .

Fukuokaya W , Mori K , Urabe F , et al . Bone-modifying agents in patients with high-risk metastatic castration-sensitive prostate cancer treated with abiraterone acetate ［J］. JAMA Netw Open , 2024 , 7 （ 3 ）: e242467 .

Wang B H , Liu C , Wei Y , et al . A prospective trial of 68 Ga-PSMA and 18 F-FDG PET/CT in nonmetastatic prostate cancer patients with an early PSA progression during castration ［J］. Clin Cancer Res , 2020 , 26 （ 17 ）: 4551 - 4558 .

Li L R , Yao H Q , Wang J , et al . The role of Chinese medicine in health maintenance and disease prevention: application of constitution theory ［J］. Am J Chin Med , 2019 , 47 （ 3 ）: 495 - 506 .

赵文硕 , 张青 , 唐武军 , 等 . 加味滋水清肝饮治疗前列腺癌去势治疗后雄激素缺乏综合征临床观察［J］. 中国中医药信息杂志 , 2010 , 17 （ 10 ）: 68 - 69 .

Zhao W S , Zhang Q , Tang W J , et al . Clinical observation on the treatment of androgen deficiency syndrome after castration treatment of prostate cancer with Jiawei Zishui Qinggan Decoction ［J］. Chin J Inf Tradit Chin Med , 2010 , 17 （ 10 ）: 68 - 69 .

Cao H W , Wang D , Gao R J , et al . Zhoushi Qiling decoction induces apoptosis of human prostate cancer cells via miR-143/Bcl-2 axis ［J］. Aging , 2021 , 13 （ 13 ）: 17202 - 17210 .

易港 . 肾气丸联合内分泌治疗激素敏感性前列腺癌的临床疗效研究［D］. 长沙 : 湖南中医药大学 , 2023 .

Feng Y G , Cao H W , Song Z X , et al . Qi Ling decoction enhances abiraterone treatment via suppression of autophagy in castration resistant prostate cancer ［J］. Aging , 2022 , 14 （ 24 ）: 9942 - 9950 .

Chen L , Xu Y X , Wang Y S , et al . Integrative Chinese-Western medicine strategy to overcome docetaxel resistance in prostate cancer ［J］. J Ethnopharmacol , 2024 , 331 : 118265 .

林文耀 , 郦俊生 , 李立 , 等 . 四君子汤联合化疗在激素抵抗性前列腺癌治疗中的应用研究［C］//中国中西医结合学会男科专业委员会. 第十二次全国中西医结合男科学术大会暨全国中西医结合男科诊疗技术研修班暨2017上海市中西医结合学会上海市中医药学会泌尿男科专业委员会学术年会讲义论文资料汇编 . 2017 : 399 .

Lin W Y , Li J S , Li L , et al . Clinical study of Sijunzi decoction combined with chemotherapy in the treatment of hormone-refractory prostate cancer ［C］// Proceedings of the 12th National Academic Conference on Andrology of Integrated Traditional Chinese and Western Medicine . 2017 : 399 .

周红 , 何秀云 , 邹清芳 . 六味地黄汤加味联合比卡鲁胺治疗晚期前列腺癌疗效观察［J］. 四川中医 , 2013 , 31 （ 6 ）: 95 - 96 .

Zhou H , He X Y , Zou Q F . Effective observation of modified Liuwei Dihuang decoction combined with bicalutamide on treating advanced prostatic cancer ［J］. J Sichuan Tradit Chin Med , 2013 , 31 （ 6 ）: 95 - 96 .

过俊杰 , 章茂森 , 朱清毅 . 清心滋肾汤对前列腺癌内分泌治疗后潮热的疗效及初步机制研究［J］. 中国实验方剂学杂志 , 2024 , 30 （ 4 ）: 152 - 158 .

Guo J J , Zhang M S , Zhu Q Y . Clinical efficacy of Qingxin zishen decoction on hot flashes after endocrine therapy for prostate cancer and its preliminary mechanism ［J］. Chin J Exp Tradit Med Formulae , 2024 , 30 （ 4 ）: 152 - 158 .

Zhang H W , Lin Z X , Cheung F , et al . Moxibustion for alleviating side effects of chemotherapy or radiotherapy in people with cancer ［J］. Cochrane Database Syst Rev , 2018 , 11 （ 11 ）: CD010559 .

Qiu J F , Wu L T , Hong Z M , et al . Hedyotis diffusae herba-Scutellaria Barbata herba drug pair suppresses prostate cancer by inducing apoptosis ［J］. Sci Rep , 2025 , 16 （ 1 ）: 2938 .

Yang B , Xie Y , Guo M J , et al . Nephrotoxicity and Chinese herbal medicine ［J］. Clin J Am Soc Nephrol , 2018 , 13 （ 10 ）: 1605 - 1611 .

Pinazo-Bandera J M , García-Cortés M , Andrade R J . AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury: also useful for hepatobiliary surgeons ［J］. Hepatobiliary Surg Nutr , 2023 , 12 （ 5 ）: 746 - 751 .

An Y , Xu J Z , Ye G C , et al . Therapeutic translation of traditional Chinese medicine Huangqi derived exosome like nanoparticles: targeting prostate cancer through ferroptosis activation, immune reprogramming, and microbiome modulation ［J］. J Nanobiotechnology , 2026 , 24 （ 1 ）: 447 .

Zou B , Long Y , Gao R S , et al . Nanodelivery system of traditional Chinese medicine bioactive compounds: application in the treatment of prostate cancer ［J］. Phytomedicine , 2024 , 135 : 155554 .

Balneaves L G , Watling C Z , Hayward E N , et al . Addressing complementary and alternative medicine use among individuals with cancer: an integrative review and clinical practice guideline ［J］. J Natl Cancer Inst , 2022 , 114 （ 1 ）: 25 - 37 .

谢洁 , 夏菁 , 季蔷 , 等 . 加速康复外科理念在机器人辅助腹腔镜下根治性前列腺切除术患者围手术期的应用［J］. 中华男科学杂志 , 2023 , 29 （ 8 ）: 736 - 740 .

Xie J , Xia J , Ji Q , et al . Application of the concept of accelerated rehabilitation surgery in the perioperative period of robot-assisted laparoscopic radical prostatectomy ［J］. Natl J Androl , 2023 , 29 （ 8 ）: 736 - 740 .

Cai M P , Song X L , Li X N , et al . Current therapy and drug resistance in metastatic castration-resistant prostate cancer ［J］. Drug Resist Updat , 2023 , 68 : 100962 .

Zhao Y R , Zhang S B , Liu B J , et al . Clinical efficacy of enhanced recovery after surgery （ERAS） program in patients undergoing radical prostatectomy: a systematic review and meta-analysis ［J］. World J Surg Oncol , 2020 , 18 （ 1 ）: 131 .

Cerantola Y , Valerio M , Persson B , et al . Guidelines for perioperative care after radical cystectomy for bladder cancer: enhanced Recovery After Surgery （ERAS ® ） society recommendations ［J］. Clin Nutr , 2013 , 32 （ 6 ）: 879 - 887 .

刘娜 . 舒适护理在改善前列腺癌腹腔镜根治术患者心理状况和降低其术后并发症的作用研究［J］. 中国卫生统计 , 2016 , 33 （ 2 ）: 278 - 279 .

Liu N . Study on the role of comfortable nursing in improving psychological status and reducing postoperative complications of patients undergoing laparoscopic radical prostatectomy ［J］. Chin J Health Stat , 2016 , 33 （ 2 ）: 278 - 279 .

Sanders J J , Temin S , Ghoshal A , et al . Palliative care for patients with cancer: ASCO guideline update ［J］. J Clin Oncol , 2024 , 42 （ 19 ）: 2336 - 2357 .

American Society of Anesthesiologists Task Force on Acute Pain Management . Practice guidelines for acute pain management in the perioperative setting: an updated report by the American Society of Anesthesiologists Task Force on Acute Pain Management ［J］. Anesthesiology , 2012 , 116 （ 2 ）: 248 - 273 .

中国抗癌协会泌尿生殖肿瘤整合康复专业委员会 . 根治性前列腺切除术围手术期整合康复中国专家共识（2024年版）［J］. 中国癌症杂志 , 2024 , 34 （ 9 ）: 890 - 902 .

Committee of Integrated Rehabilitation for Urogenital Tumors, Chinese Anti-Cancer Association . Chinese expert consensus on perioperative integrated rehabilitation for radical prostatectomy（2024 edition）［J］. China Oncol , 2024 , 34 （ 9 ）: 890 - 902 .

戴韻 , 王薇 , 毛祺琦 , 等 . 术前盆底肌训练对根治性前列腺切除术后尿控恢复的影响［J］. 中华泌尿外科杂志 , 2014 , 35 （ 11 ）: 879 - 880 .

Dai Y , Wang W , Mao Q Q , et al . Effect of preoperative pelvic floor muscle training on urinary control recovery after radical prostatectomy ［J］. Chin J Urol , 2014 , 35 （ 11 ）: 879 - 880 .

Anesthesiologists Branch of Chinese Medical Doctor Association , Urologists Branch of Chinese Medical Doctor Association . ERAS China expert consensus and path management expert consensus (2018): radical prostate cancer surgery ［J］. J Clin Anesthesiol , 2018 , 34 ( 6 ): 602 - 608 .

李晓玲 , 林红云 , 栗霞 . 前列腺癌根治术后尿失禁病人行盆底肌综合康复锻炼效果观察［J］. 护理研究（中旬版） , 2008 （ 12 ）: 3238 - 3239 .

Li X L , Lin H Y , Li X . Observation on effect of pelvic floor muscles comprehensive rehabilitation exercise for prostate cancer patients with urinary incontinence after undergoing radical surgery ［J］. Chin Nurs Res , 2008 （ 12 ）: 3238 - 3239 .

Hsu L F , Liao Y M , Lai F C , et al . Beneficial effects of biofeedback-assisted pelvic floor muscle training in patients with urinary incontinence after radical prostatectomy: a systematic review and meta-analysis ［J］. Int J Nurs Stud , 2016 , 60 : 99 - 111 .

Meisterhofer K , Herzog S , Strini K A , et al . Male slings for postprostatectomy incontinence: a systematic review and meta-analysis ［J］. Eur Urol Focus , 2020 , 6 （ 3 ）: 575 - 592 .

Goode P S , 2nd Johnson T M , Newman D K , et al . Perioperative mobile telehealth program for post-prostatectomy incontinence: a randomized clinical trial ［J］. J Urol , 2022 , 208 （ 2 ）: 379 - 387 .

Al Hussein Al Awamlh B , Wallis C J D , Penson D F , et al . Functional outcomes after localized prostate cancer treatment ［J］. JAMA , 2024 , 331 （ 4 ）: 302 - 317 .

van den Berg I , Spaans R N , Wessels F J , et al . Automated pelvic MRI measurements associated with urinary incontinence for prostate cancer patients undergoing radical prostatectomy ［J］. Eur Radiol Exp , 2024 , 8 （ 1 ）: 1 .

Lenis A T , Ravichandran V , Brown S , et al . Microsatellite instability, tumor mutational burden, and response to immune checkpoint blockade in patients with prostate cancer ［J］. Clin Cancer Res , 2024 , 30 （ 17 ）: 3894 - 3903 .

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

经直肠高强度聚焦超声局灶消融治疗前列腺癌的回顾性队列研究

2025年乳腺癌精准治疗的进展与展望

MYC通过靶向CD47促进前列腺癌增殖和转移的机制研究

Ptenfl/fl;Trp53fl/fl;Pbsn-iCre+基因编辑小鼠自发形成前列腺癌与乳腺癌的模型构建研究

根治性前列腺切除术围手术期整合康复中国专家共识（2024年版）